JUAN (JOHN) A. FERNANDEZ, MD

Curriculum Vitae

American Board of Physician Specialties, Board Certified
Specialty: Internal Medicine
Subspecialty: Nephrology, Hypertension & Transplantation

Juan A. Fernandez M.D., PA **1996-Present**
South Florida Kidney Partners
President & Managing Partner

~~5040 N.W. 7th St. Suite #370~~
Miami, Florida 33126

8061 N.W. 155th Street
Miami Lakes, Florida 33016

10/Feb 2000

CLINICAL RESEARCH EXPERIENCE

Total Research Group, LLC
Principal Investigator

University of Miami/Jackson Memorial Hospital Nephrology & Transplantation
Clinical Research Investigator

University of Miami/School of Medicine, Department of Clinical Pharmacology
Clinical Research Investigator

PROFESSIONAL LICENSES

Florida Medical License: ME - 0068513
DEA Registration: BF - 4485896

AFFILIATIONS

Total Research Group, LLC
5040 NW 7 Street, Suite 370
Miami, FL 33126

MEDICAL STAFF EXECUTIVE POSITIONS

Coral Gables Hospital (Tenet)	
Physician Advisor	2017 – Present
Medical Staff President	2016 – 2018
	2008 – 2010
Board of Trustees Member	2019 - Present
Medical Executive Board	2010 - Present
Governing Board Member	2015 - Present
Hialeah Hospital (Tenet)	
Physician Advisor	2018 – Present
Kindred Hospital	2015 – 2018
Medical Staff President	2012 - 2014
Promise Hospital	2014 - 2018
Medical Staff President	2019 - Present
Medical Director	
	2012 – 2019
Select Sub-Specialty Hospital	
Medical Executive Board Member	

DIALYSIS EXPERIENCE

South Florida Dialysis Center - Medical Director (2013 – Present)
Ultimate Care Dialysis Center – Medical Director (2014 - 2018)

Apollo Renal Center – Staff Nephrologist (Present), Past Medical Director
ARC Miami - Staff Nephrologist (Present), Past Medical Director
Olympus Acute Dialysis – Past Medical Director

CLINICAL EXPERIENCE

Georgetown University/Franklin Square Medical Center Internship, Internal Medicine	1/82 - 12/82
Georgetown University/Franklin Square Medical Center Residency, Internal Medicine	1/83 -12/84
Georgetown University/Franklin Square Medical Center Chief Resident, Internal Medicine	1/85 - 12/85
University of Miami School of Medicine, Department of Clinical Pharmacology Clinical Research Fellow	6/86 - 8/87
University of Miami/Jackson Memorial Hospital Nephrology & Transplantation Clinical and Research Fellow	9/87 - 9/92

ACADEMIC EXPERIENCE

FIU School of Medicine, International Program Associate Dean	2017- Present
FIU School of Medicine, Physician Assistant Program Adjunct Professor	2014 – Present
FIU School of Medicine, International Studies Adjunct Professor of Medicine	2005 - Present
Barry University School of Health Sciences Adjunct Professor	1993 - 1995
Kemper National Medical Insurance Services Co. Physician Advisor, Assistant Medical Director	1993 - 1995

COMMUNITY POSITIONS

Miami Rescue Mission – Board Member	2015 - Present
Team Physician - University of Miami Hurricanes	1995 - 2010
Team Physician - Belen Jesuit Wolverines	1995 - 2015

EDUCATION

Northeastern Catholic University, Doctorate in Medicine 1981
Doctoral Thesis:

Studies on Medical and Surgical Therapy for Peptic Ulcer Disease with H2 Blockers and Laparoscopy

CERTIFICATIONS

Federation of State Medical Boards (Diplomat)
American Board of Physician Specialties (Diplomat)
CITI Good Clinical Practice - Certified

PUBLICATIONS

BOOKS

Burke GW, Fernandez JA, Koleilat N, Roth D, Nery J, Miller 1. Serial assessment of kidney transplant function with radionuclide imaging. In Atlas of Renal Scintigraphy in Congenital and Acquired Disorders and in Complications of Renal Transplants. Douglas Van Norstrand, Editor. Springer- Verlang Publisher, 1991.

JOURNAL ARTICLES

1. Roth D, Alarcon FJ, Fernandez JA, Preston R, Bourgoignie J. Acute rhabdomyolysis associated with cocaine intoxication. N. Engl. 1. Med., 319:673, 1998.

2. Ortiz C, Meneses R, Jaffe D, Fernandez JA, Perez G, Bourgoignie JJ. Outcome of patients with immunodeficiency virus on maintenance hemodialysis. Kid. Int., 34:248, 1988.

3. Ranjan D, Fernandez JA, Burke G, Esquenazi V, Roth D, Kolielat N, Miller 1. Hepatitis related risk factors in renal transplant recipients and donors. Surgical Forum, 61: 400, 1990.

4. Fernandez JA, Milgrom M, Burke G, Miller J, Roth D. Recurrence of lupus nephritis in a renal allograft with transformation of the lesion. Transplantation, 50: 1056, 1990.

5. Fernandez JA, Roth D, Burke G, Ranjan D, Esquenazi V, Miller Detection of antibody to hepatitis C virus in renal transplant recipients. Transplantation Pro., 23:444, 1991.

6. Miller J, Esquenazi Y, Fuller L, Zucker K, Roth D, Fernandez JA, Burke G, Nery J. The immonologic response to allografts: Acute rejection. Clin. Transplantation, 5:477, 1991.

7. Silva M, Roth D, Fernandez JA, Reddy R, Saavedra .fA, Schiffe. Hepatic dysfunction accompanying acute cocaine intoxication. Journal ofHepatology, 12:312, 1991.

8. Roth D, Fernandez JA, Burke G, Esquenazi Y, Miller 1. Detection of Anti-HCY in kidney transplant patients. Transplantation, 51 : 3 96, 1991

9. Fuller L, Fernandez JA, Zheng S, Carreno M, Esquenazi V, Yang J, Miller J. Immune and biochemical characterization of purified canine interferon: Purification of monoclonal antibody, a Ifinity , and its effect on Ml.C and ivfLKC reactions. Transplantation, in press.

10. Fernandez JA, Roth D, Burke G, Nery J, Babischkin S, Esquenazi V, Miller J. Viral diseases in transplantation. Clinical Transplantation, in press.

11. Roth D, Fernandez JA, Babischkin S, Mattos A, Buck B, Quail S, Olson L, Burke G, Nery J, Esquenazi Y, Schiff E, Miller 1. Detection of hepatitis C virus infection among cadaver organ donors and evidence for transmission of disease. Ann. Int. Med., 117:470, 1992.

12. Burke G, Cirocco R, Roth D, Fernandez JA, Allouche M, Markou M, Reddy R, Jeffers L, Schiffe, Nery J, Miller 1. Activated cytokine pattern in hepatorenal syndrome: fall in levels after successful orthotopic liver transplantation.

ABSTRACTS & PRESENTATIONS

1. Fernandez JA, Roth D, Burke G, Esquenazi Y, Miller 1. Detection of antibody to hepatitis C virus in renal allograft recipients. Am. Soc. Nephorol.

2. Fernandez JA.Fuller L, Zheng S, Carreno M, Esquenazi V, Yang J, Miller 1. Isolation of dog interferon, production ofMAb and their regulatory effects ofMLC, MLKC and MLIC. American Society of Transplant Physicians

3. Fernandez JA, Fuller L, Zheng S, Carreno M, Esquenazi V, Yang J, Miller J. Mixed lymphocyte kidney and islet cell co-cultures: the effect of interferon-gamma and anti-inferon- gama. American Society of Transplant Physicians

4. Fernandez JA, Roth D, Burke G, Nery J, Esquenazi Y, Miller 1. Preemptive kidney transplantation in the diabetic patient. American Society of Transplant Physicians

OTHER WORKS & PUBLICATIONS

1. Characterization of anti-canine cytokine monoclonal antibodies specific for interferon and tumor necrosis factor. Carreno M, Fuller L, Zucker K, Asthana D, Fernandez JA, Yang J, Esquenazi Y, Guber S, Miller J. American Society of Histocompatibility and Immunogenetics

2. Molecular monitoring of cyclosporine in renal transplant patients. Koutouby R, Zucker K, Fernandez JA, Roth D, Burke G, Nery J, Esquenazi V, Miller American Society of Transplant Physicians,

3. The impact of long term double vs triple immunosuppressive therapy for cadaveric renal transplant recipients. Roth D. Fernandez JA, Burke G, Esquenazi V, Miller J. American Society of Nephrology

PHARMACEUTICAL RESEARCH

1. **Retrophin, Inc. – Principal Investigator –** Phase 3, A Randomized, Multicenter, Double-Blind, Parallel, Active-Control Study of the Effects of XXX, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)

2. **Ardelyx, Inc. – Principal Investigator** -Phase 3, A Long-Term, Open Label Study to Evaluate the Ability of XXX Alone or in Combination with Sevelamer to Treat to Goal Serum Phosphorus in Patients with ESRD on Dialysis.

3. **Astra Zeneca - Principal-Investigator** - A Phase 3: Amendment 3 to Clinical Study. A Multicenter, Randomized, Double blind, placebo-controlled study Evaluating the Safety and Efficacy of XXX for the Treatment of Anemia in Chronic CKD Patients not on dialysis

4. **OPKO Renal Division – Principal Investigator** – Mineral and Bone Disorder in Pre-dialysis: A Real-World Assessment of Risk and Effectiveness of Current SHPT Treatment Approaches (MBD-AWARE)

5. **Akebia, Inc – Principal Investigator** – Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral XXX for the Correction of Anemia in Subjects with Non-Dialysis-Dependent Chronic Kidney Disease.

6. **Akebia, Inc – Principal Investigator** – Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral XXX for the Maintenance Treatment of Anemia in Subjects with Non-Dialysis-Dependent Chronic Kidney Disease.

7. **Ardelyx, Inc. – Principal Investigator** - A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of XXX as Adjunctive Therapy to Phosphate Binder Therapy in End Stage Renal Disease subjects with Hyperphosphatemia.

8. **Akebia, Inc. – Principal Investigator** – Phase 2, Randomized, Open-Label, Active-Controlled, Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics study of Oral XXX for the Treatment of Anemia in Hemodialysis Subjects Converting from Epoitin alfa.

9. **Ardelyx, Inc. – Principal Investigator** - A Phase 3, Open Label Study with a 12-Week, Placebo-Controlled, Randomized Withdrawal Period Followed by an Open Label Long Term Safety Extension to Evaluate the Safety and Efficacy of XXX to Treat Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis and Peritoneal Dialysis.

10. **GlaxoSmithKline - Principal-Investigator** – A open-label (sponsor-blind), randomized, active controlled, parallel-group, multi-center study to evaluate the efficacy and safety of XXX compared to recombinant human erythropoietin in subjects with anemia associated with CKD who are initiating dialysis.

11. **GlaxoSmithKline - Principal-Investigator** - A phase 3 randomized, open-label (sponsor-blind), active controlled, event driven study in non-dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of XXX compared to darbepoetin alfa

12. **GlaxoSmithKline - Principal-Investigator** - A phase 3 randomized, open-label (sponsor-blind), active controlled, event driven study in dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of XXX compared to recombinant human erythropoietin, following a switch from erythropoietin-stimulating agents

13. **Astra-Zeneca - Principal-Investigator** - A Phase 3: multicenter, randomized, double blind, placebo-controlled study evaluating the safety and Efficacy of XXX for the Treatment of Anemia in Chronic CKD Patients not on dialysis

14. **Zoll LLC - Principal-Investigator** - Wearable cardioverter defibrillator in hemodialysis patients (WED-HED) study

15. **Astra-Zeneca Principal-Investigator** - A phase 3, multicenter, randomized, double blind placebo-controlled study in anemic patients with CKD 3, 4, or 5 not on dialysis.

16. **Takeda Corporation - Principal-Investigator** - XXX a phase 3 selective inhibitor xanthine oxidase in patients with renal impairment

17. **Genkyotex - Principal-Investigator** - A double-blind randomized placebo controlled, Phase 2 evaluating the safety and efficacy of oral XXX in patients with type 2 diabetes and albuminuria

18. **Ciba-Geigy Corp - Principal-Investigator** - Pilot Bioavailability study evaluating a single dose of oral solution XXX given on four separate occasions

19. **Pfizer Labs - Principal-Investigator** - Phase 1 double blind placebo controlled single dose study to establish toleration and pharmacokinetics of XXX

20. **Pfizer Labs - Principal-Investigator -** A phase 1 study of the bioequivalence of the research and proposed commercial pediatric formulations of XXX.

21. **Pfizer Labs - Principal-Investigator -** A phase 1 study of the bioequivalence of the research and proposed commercial tablet formulations of XXX.

22. **Syntex Research - Principal-Investigator** - Safety and pharmacokinetic study of a single intravenous dose of XXX.

23. **Duramed Pharmaceuticals - Principal-Investigator** - Comparative randomized 2-way crossover bioavailability study of XXX and Upjohn methylprednisolone

24. **Pfizer Labs - Principal-Investigator -** Single dose study of XXX in obese otherwise healthy volunteers.

25. **Pfizer Labs - Principal-Investigator -** Phase 1 study comparing the bioequivalence of sertraline commercial tablet and capsule with XXX research capsule

26. **Pfizer Labs - Principal-Investigator -** Phase 1 double-blind, placebo controlled single dose study to establish toleration, pharmacokinetics and bioavailability of XXX.

27. **Bristol-Myers - Principal-Investigator** - A multi-dose human safety and pharmacokinetic study of XXX.

HONORS & AWARDS

A.M.A. Physician Recognition Award National Health Council Volunteer Organization Award
Fellow of the Inter-American College of Physicians & Surgeons

MEMBERSHIPS

Renal Physicians Association
American Society of Nephrology
American Society of Hypertension
American Society of Transplant Physicians
Association of American Colleges